Aqueous composition
Incorporating chlorhexidine into aqueous compositions stabilizes brimonidine, addressing instability issues and maintaining pharmaceutical quality by suppressing content reduction.
Patent Information
- Application Number
- JP2024165820
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-09-25
- Publication Date
- 2024-12-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Aqueous compositions containing brimonidine are prone to instability due to reactions with water, leading to a decrease in active ingredient content, which affects the quality and stability of pharmaceuticals.
Incorporating an amino compound, such as chlorhexidine, into the aqueous composition stabilizes brimonidine by suppressing its content reduction during high-temperature storage.
The addition of chlorhexidine enhances the stability of brimonidine in aqueous compositions, maintaining its content and ensuring the quality of pharmaceuticals.
Smart Images

Figure 2024169649000001 
Figure 2024169649000002 
Figure 2024169649000003
Abstract
Description
[Technical field]
[0001] The present invention relates to an aqueous composition. [Background technology]
[0002] Brimonidine, such as brimonidine tartrate (chemical name: 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxaline-6-amine mono-(2R,3R)-tartrate), is a type of adrenergic α2 receptor agonist that inhibits aqueous humor production and promotes aqueous humor outflow from the uveoscleral outflow pathway and exhibits excellent intraocular pressure reducing effects, and is therefore used as an active ingredient in ophthalmic agents such as drugs for treating ocular hypertension and glaucoma (Non-Patent Document 1). Ophthalmic agents are usually compositions containing water (aqueous compositions), and various studies have been conducted on aqueous compositions containing brimonidine (e.g., Patent Documents 1 and 2, etc.). [Prior art documents] [Patent documents]
[0003] [Patent Document 1] Special Publication No. 2004-504279 [Patent Document 2] JP 2012-246304 A [Non-patent literature]
[0004] [Non-Patent Document 1] Aiphagan (registered trademark) eye drops 0.1% Pharmaceutical interview form, Senju Pharmaceutical Co., Ltd. May 2013 (revised 4th edition) Summary of the Invention [Problem to be solved by the invention]
[0005] Although aqueous compositions have the advantages of being gentle to living organisms such as ocular tissues and excellent in safety because they contain water, and being easy to handle during production and use, the active ingredient is easily destabilized due to reactions via water, etc. By improving the stability of aqueous compositions containing brimonidine, it is possible to provide pharmaceuticals and the like with higher quality. Therefore, an object of the present invention is to provide a technique for improving the stability of brimonidine in an aqueous composition. [Means for solving the problem]
[0006] Therefore, the present inventors have conducted extensive research to solve the above problems and have surprisingly found that by further adding an amino compound, typically chlorhexidine, to an aqueous composition containing brimonidine, the decrease in the brimonidine content in the aqueous composition during high-temperature storage can be suppressed, thereby completing the present invention.
[0007] That is, the present invention relates to a composition comprising the following components (A) and (B): (A) brimonidine or a salt thereof or a solvate thereof; (B) an amino compound; The present invention provides an aqueous composition comprising:
[0008] The present invention also provides a composition comprising the following component (A): (A) brimonidine or a salt thereof or a solvate thereof; The aqueous composition contains the following component (B): (B) an amino compound; The present invention provides a method for stabilizing brimonidine or a salt thereof, or a solvate thereof in an aqueous composition, comprising: Effect of the Invention
[0009] According to the present invention, it is possible to provide an aqueous composition having excellent stability by suppressing the decrease in the brimonidine content in the aqueous composition during storage at high temperatures. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] <Brimonidine or its salt or solvate> In the present specification, "brimonidine or its salt or solvate thereof" includes not only brimonidine but also pharmacologically acceptable salts of brimonidine, and further includes solvates of brimonidine or its pharmacologically acceptable salts with water, alcohol, etc. Pharmacologically acceptable salts are not particularly limited, but specifically include, for example, inorganic acid salts such as hydrochloride, sulfate, nitrate, hydrofluoride, hydrobromide, etc.; organic acid salts such as acetate, tartrate, lactate, citrate, fumarate, maleate, succinate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, naphthalenesulfonate, camphorsulfonate, etc., and among them, tartrate is preferred.
[0011] As brimonidine or a salt thereof, or a solvate thereof, brimonidine and brimonidine tartrate (brimonidine monotartrate) (chemical name: 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxaline-6-amine mono-(2R,3R)-tartrate) are preferred. Brimonidine or a salt thereof, or a solvate thereof is known and may be produced by a known method, or a commercially available product may be used.
[0012] The content of brimonidine or a salt thereof, or a solvate thereof in the aqueous composition is not particularly limited and may be determined appropriately depending on the applicable disease, the sex, age, symptoms, etc. of the patient. From the viewpoint of obtaining an excellent pharmacological effect, however, the content is preferably 0.01 to 10 w / v% relative to the total volume of the aqueous composition, more preferably 0.02 to 1 w / v%, and particularly preferably 0.06 to 0.5 w / v%.
[0013] <Amino compounds> In the present specification, the term "amino compound" refers to one or more selected from the group consisting of compounds having one or more amino groups, their salts, and solvates thereof. Here, the salt is not particularly limited as long as it is a pharma- cologically acceptable salt, and specific examples thereof include inorganic acid salts such as hydrochloride, sulfate, nitrate, hydrofluoride, and hydrobromide; organic acid salts such as acetate, tartrate, lactate, citrate, gluconate, fumarate, maleate, succinate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, naphthalenesulfonate, and camphorsulfonate; and metal salts such as sodium salt, potassium salt, lithium salt, calcium salt, and magnesium salt. Furthermore, the amino compound may be a solvate such as a hydrate or alcohol solvate.
[0014] Examples of the amino compound include one or more selected from the group consisting of aliphatic amines and their salts and solvates thereof which may have a substituent, one or more selected from the group consisting of aromatic amines and their salts and solvates thereof which may have a substituent, and one or more selected from the group consisting of compounds having a carbamoyl group which may have a substituent, their salts and solvates thereof which may have a substituent, etc. The substituent is not particularly limited, and examples thereof include a halogeno group, a carboxyl group, a hydroxyl group, a sulfonic acid group, a guanidino group, a carbamoyl group, a mercapto group, an imidazolyl group, a methylthio group, a phenyl group, an indolyl group, an ethoxycarbonyl group, etc., and one or more of these may be substituted in combination.
[0015] Specific examples of the at least one selected from the group consisting of aliphatic amines and their salts and solvates thereof that may have a substituent include at least one selected from the group consisting of aliphatic primary amines and their salts and solvates thereof that may have a substituent, at least one selected from the group consisting of aliphatic secondary amines and their salts and solvates thereof that may have a substituent, at least one selected from the group consisting of aliphatic tertiary amines and their salts and solvates thereof that may have a substituent. In this case, the aliphatic group is not particularly limited, but from the viewpoint of the suppressive effect of the decrease in the content of brimonidine or its salt or its solvate, a straight-chain or branched-chain aliphatic group having 1 to 12 carbon atoms is preferred, a straight-chain or branched-chain aliphatic group having 2 to 10 carbon atoms is more preferred, and a straight-chain or branched-chain aliphatic group having 2 to 6 carbon atoms is particularly preferred.
[0016] Specific examples of the one or more selected from the group consisting of optionally substituted aliphatic primary amines, salts thereof, and solvates thereof include L-aspartic acid, sodium L-aspartate, potassium L-aspartate, magnesium L-aspartate, DL-alanine, L-alanine, L-arginine, L-arginine hydrochloride, epsilon-aminocaproic acid, glycine, L-glutamine, L-glutamic acid, L-glutamic acid hydrochloride, potassium L-glutamate, sodium L-glutamate, L-cystine, L-cysteine, L-cysteine hydrochloride hydrate, L-histidine, L-histidine hydrochloride hydrate, L- Examples of the aliphatic primary amines include aliphatic primary amines (amino acids) having at least a carboxyl group as a substituent, such as phenylalanine, DL-methionine, L-methionine, L-lysine, L-lysine hydrochloride, dl-leucine, L-leucine, etc.; aliphatic primary amines having a hydroxyl group as a substituent, such as trometamol, monoethanolamine, etc.; aliphatic primary amines having a sulfonic acid group as a substituent, such as taurine; aliphatic primary amines having at least a phenyl group as a substituent, such as netarsudil mesylate (preferably dimesylate) or other netarsudil or a salt thereof, or a solvate thereof; and unsubstituted aliphatic primary amines, such as ethylenediamine. Specific examples of the one or more selected from the group consisting of aliphatic secondary amines which may have a substituent, salts thereof, and solvates thereof include aliphatic secondary amines having at least a hydroxyl group as a substituent, such as carteolol hydrochloride (preferably the monohydrochloride) or a salt thereof, or a solvate thereof, and timolol maleate (preferably the monomaleate) or a salt thereof, or a solvate thereof; aliphatic secondary amines having at least a guanidino group as a substituent, such as chlorhexidine hydrochloride (preferably the dihydrochloride), chlorhexidine gluconate (preferably the digluconate), chlorhexidine acetate (preferably the diacetate), or a salt thereof, or a solvate thereof; and aliphatic secondary amines having at least an isopropoxycarbonyl group as a substituent, such as omidenepagisopropyl or a salt thereof, or a solvate thereof. Specific examples of the one or more selected from the group consisting of optionally substituted aliphatic tertiary amines, salts thereof, and solvates thereof include aliphatic tertiary amines having a carboxyl group as a substituent, such as calcium disodium edetate, sodium edetate hydrate, and tetrasodium edetate. Specific examples of the at least one selected from the group consisting of aromatic amines which may have a substituent, salts thereof, and solvates thereof include ethyl aminobenzoate. Furthermore, specific examples of the one or more compounds selected from the group consisting of compounds having a carbamoyl group which may have a substituent, salts thereof, and solvates thereof include ethyl urea, urea, phenprobamate, etc. These amino compounds are all known and may be produced by known methods or may be commercially available products. Furthermore, the amino compounds may form salts or complexes with other components.
[0017] From the viewpoint of the inhibitory effect on the content of brimonidine or a salt thereof, or a solvate thereof, the amino compound is preferably one or more selected from the group consisting of an aliphatic amine which may have a substituent, a salt thereof, and a solvate thereof, more preferably one or more selected from the group consisting of an aliphatic primary to tertiary (preferably secondary) amine which may have a substituent, a salt thereof, and a solvate thereof, and the substituent is preferably a carboxyl group, a hydroxyl group, a sulfonic acid group, a guanidino group, a carbamoyl group, a mercapto group, an imidazolyl group, a methylthio group, or a phenyl group (preferably More preferred are aliphatic primary to tertiary (preferably secondary) amines having 1 to 12 carbon atoms (preferably 2 to 10, particularly preferably 2 to 6 carbon atoms), which may have one or more (preferably 1 to 4) selected from the group consisting of a carboxyl group, a hydroxyl group, a sulfonic acid group, a guanidino group, and an imidazolyl group, and salts thereof and solvates thereof, and further preferred are aspartic acid, alanine, arginine, epsilon-aminocaproic acid, edetic acid, glycine, glutamine, glutamic acid, cystine, cysteine, histidine, phenylalanine, methionine, More preferably, the compound is one or more selected from the group consisting of arginine, epsilon-aminocaproic acid, glutamic acid, taurine, histidine, lysine, trometamol, monoethanolamine, taurine, ethylenediamine, chlorhexidine, edetic acid, salts thereof, and solvates thereof. More preferably, the compound is one or more selected from the group consisting of arginine, epsilon-aminocaproic acid, glutamic acid, taurine, histidine, lysine, trometamol, monoethanolamine, ethylenediamine, chlorhexidine, edetic acid, salts thereof, and solvates thereof. More preferably, the compound is one or more selected from the group consisting of chlorhexidine, edetic acid, and solvates thereof. More preferably, the compound is one or more selected from the group consisting of chlorhexidine, its salts, and solvates thereof; even more preferably, the compound is one or more selected from the group consisting of chlorhexidine, chlorhexidine hydrochloride, chlorhexidine gluconate, chlorhexidine acetate, and solvates thereof; even more preferably, the compound is one or more selected from the group consisting of chlorhexidine hydrochloride and chlorhexidine gluconate solutions listed in the Japanese Pharmacopoeia, 17th Edition;Chlorhexidine gluconate solution listed in the 17th edition of the Japanese Pharmacopoeia is particularly preferred.
[0018] The content of the amino compound in the aqueous composition is not particularly limited, but from the viewpoint of suppressing the decrease in the content of brimonidine or its salt or their solvates, it is preferably contained in total of 0.00001-10 w / v%, more preferably contained in 0.00005-5 w / v%, and particularly preferably contained in 0.0001-1 w / v% based on the total volume of the aqueous composition. In particular, when one or more selected from the group consisting of chlorhexidine and its salts and their solvates are used as the amino compound, from the viewpoint of suppressing the decrease in the content of brimonidine or its salt or their solvates, it is preferably contained in total of 0.0001-0.1 w / v%, more preferably contained in 0.0005-0.05 w / v%, and particularly preferably contained in 0.001-0.01 w / v% based on the total volume of the aqueous composition.
[0019] Furthermore, the mass ratio of brimonidine or a salt thereof, or a solvate thereof to the amino compound in the aqueous composition is not particularly limited, but from the viewpoint of inhibiting a decrease in the content of brimonidine or a salt thereof, or a solvate thereof, the aqueous composition preferably contains a total of 0.00005 to 100 parts by mass of amino compound per part by mass of brimonidine or a salt thereof, or a solvate thereof, calculated as the free form, more preferably 0.0005 to 50 parts by mass, and particularly preferably 0.005 to 5 parts by mass. In particular, when the amino compound is one or more selected from the group consisting of chlorhexidine and its salts, and solvates thereof, from the viewpoint of inhibiting a decrease in the content of brimonidine or its salts, or their solvates, it is preferable to contain a total of 0.0001 to 10 parts by mass, more preferably 0.001 to 1 part by mass, and particularly preferably 0.01 to 0.1 part by mass of chlorhexidine and its salts, and their solvates, per part by mass of brimonidine or its salts, or their solvates, calculated as their free forms.
[0020] In this specification, "aqueous composition" means a composition containing at least water, and its properties include liquid (solution or suspension) and semi-solid (ointment), and liquid is preferred. The water in the composition can be, for example, purified water, water for injection, sterilized purified water, etc. The water content in the aqueous composition is not particularly limited, but is preferably 5% by mass or more, more preferably 20% by mass or more, even more preferably 50% by mass or more, even more preferably 90% by mass or more, and particularly preferably 90 to 99.9% by mass.
[0021] The aqueous composition can be made into various dosage forms according to known methods described in, for example, the General Provisions for Preparations of the 16th Edition of the Japanese Pharmacopoeia. Examples of dosage forms include injections, inhalation solutions, eye drops, eye ointments, ear drops, nasal drops, enemas, external solutions, sprays, ointments, gels, oral solutions, and syrups. From the viewpoint of advantageously utilizing the pharmacological action of brimonidine, the dosage form is preferably an ophthalmic preparation, specifically, eye drops and eye ointments, and more preferably, eye drops.
[0022] The aqueous composition may contain additives used in pharmaceuticals, quasi-drugs, etc., depending on the dosage form. Examples of such additives include inorganic salts, isotonicity agents, chelating agents, stabilizers, pH regulators, preservatives, antioxidants, thickening agents, surfactants, solubilizers, suspending agents, refreshing agents, dispersants, preservatives, oily bases, emulsion bases, water-soluble bases, etc. The above-mentioned "amino compounds" may also be used as such additives. Specific examples of such additives include ascorbic acid, sodium bisulfite, alginic acid, sodium benzoate, benzyl benzoate, fennel oil, ethanol, ethylene-vinyl acetate copolymer, potassium chloride, calcium chloride hydrate, sodium chloride, magnesium chloride, hydrochloric acid, carboxyvinyl polymer, dry sodium sulfite, dry sodium carbonate, d-camphor, dl-camphor, xylitol, citric acid hydrate, sodium citrate hydrate, glycerin, gluconic acid, chlorobutanol, crystalline sodium dihydrogen phosphate, geraniol, Sodium chondroitin sulfate, acetic acid, potassium acetate, sodium acetate hydrate, titanium dioxide, gellan gum, dibutyl hydroxytoluene, potassium bromide, benzododecinium bromide, tartaric acid, sodium hydroxide, polyoxyl 45 stearate, purified lanolin, D-sorbitol, sorbitol solution, sodium bicarbonate, sodium carbonate hydrate, sodium thiosulfate hydrate, thimerosal, tyloxapol, sodium dehydroacetate, concentrated glycerin, concentrated mixed tocopherols, white petrolatum, peppermint water, peppermint oil, concentrated benzalkonium chloride solution 50, Palau Ethyl parahydroxybenzoate, butyl parahydroxybenzoate, propyl parahydroxybenzoate, methyl parahydroxybenzoate, sodium hyaluronate, human serum albumin, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, glacial acetic acid, sodium pyrosulfite, phenylethyl alcohol, glucose, propylene glycol, bergamot oil, benzalkonium chloride, benzalkonium chloride solution, benzyl alcohol, benzethonium chloride, benzethonium chloride solution, borax, boric acid, povidone, polyoxyethylene (200) polyoxy Propylene glycol (70), sodium polystyrene sulfonate, polysorbate 80, polyoxyethylene hydrogenated castor oil 60, polyvinyl alcohol (partially saponified), d-borneol, macrogol 4000, macrogol 6000, D-mannitol, anhydrous citric acid, anhydrous sodium monohydrogen phosphate, anhydrous sodium dihydrogen phosphate, methanesulfonic acid, methylcellulose, l-menthol, aluminum monostearate, polyethylene glycol monostearate, eucalyptus oil, potassium iodide, sulfuric acid, oxyquinoline sulfate, liquid paraffin,Examples of the antioxidant include rhodium, phosphoric acid, sodium hydrogen phosphate hydrate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sodium dihydrogen phosphate monohydrate, sodium dihydrogen phosphate dihydrate, malic acid, and petrolatum.
[0023] Examples of additives include potassium chloride, calcium chloride hydrate, sodium chloride, magnesium chloride, hydrochloric acid, glycerin, acetic acid, potassium acetate, sodium acetate hydrate, tartaric acid, sodium hydroxide, sodium bicarbonate, sodium carbonate hydrate, concentrated glycerin, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, borax, boric acid, povidone, polysorbate 80, polyoxyethylene hydrogenated castor oil 60, polyethylene glycol monostearate, polyvinyl alcohol (partially saponified), macrogol 4000, macrogol 6000, anhydrous citric acid, anhydrous sodium monohydrogen phosphate, anhydrous sodium dihydrogen phosphate, methylcellulose, phosphoric acid, sodium hydrogen phosphate hydrate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sodium dihydrogen phosphate monohydrate, sodium dihydrogen phosphate dihydrate, sodium hyaluronate, glucose, and l-menthol.
[0024] The aqueous composition may further contain other medicinal ingredients in addition to those mentioned above, depending on the disease to be treated, etc.Examples of such medicinal ingredients include α1 receptor blockers including bunazosin, such as bunazosin hydrochloride, or a salt thereof, or a solvate thereof; α2 receptor agonists including apraclonidine, a salt thereof, or a solvate thereof; nipradilol, a salt thereof, or a solvate thereof; betaxolol, such as betaxolol hydrochloride, or a salt thereof, or a solvate thereof; levobunolol, such as levobunolol hydrochloride, or a salt thereof, or a solvate thereof; befunolol, a salt thereof, or a solvate thereof; metipranolol, a salt thereof, or a solvate thereof; beta-blockers including solvates thereof; dorzolamide such as dorzolamide hydrochloride or its salts or solvates thereof, brinzolamide or its salts or solvates thereof, acetazolamide or its salts or solvates thereof, dichlorphenamide or its salts or solvates thereof, carbonic anhydrase inhibitors including methazolamide or its salts or solvates thereof; isopropyl unoprostone or its salts or solvates thereof, tafluprost or its salts or solvates thereof, travoprost or its salts or solvates thereof, bimatoprost or its salts or solvates thereof, prostaglandins including prost or its salts or solvates thereof, latanoprost or its salts or solvates thereof, cloprostenol or its salts or solvates thereof, and fluprostenol or its salts or solvates thereof; sympathomimetics including dipivefrin or its salts or solvates thereof such as dipivefrin hydrochloride, epinephrine, epinephrine borate, epinephrine hydrochloride, or its salts or solvates thereof; distigmine bromide or its salts or solvates thereof, pilocaloride or its salts or solvates thereof, parasympathomimetics including pilocarpine, pilocarpine hydrochloride, pilocarpine nitrate, or other salts or solvates thereof, carbachol, a salt or a solvate thereof; calcium antagonists including lomerizine, such as lomerizine hydrochloride, or other salts or solvates thereof; cholinesterase inhibitors including demecarium, a salt or a solvate thereof, echothiophate, a salt or a solvate thereof, and physostigmine, a salt or a solvate thereof, and these can be used alone or in combination.The aqueous composition may not contain Ripasudil, such as Ripasudil hydrochloride hydrate, or a salt thereof, or a solvate thereof. The other active ingredient is preferably one or more selected from the group consisting of latanoprost, nipradilol, dorzolamide, brinzolamide, and salts thereof.
[0025] The pH (25° C.) of the aqueous composition is not particularly limited, but is preferably 4 to 8.5, more preferably 5 to 8, and particularly preferably 6 to 7.5. The osmotic pressure ratio to physiological saline is not particularly limited, but is preferably 0.6 to 3, and more preferably 0.6 to 2.
[0026] The aqueous composition is preferably contained in a container from the viewpoints of storage stability, portability, etc. The form of the container is not particularly limited as long as it can contain the aqueous composition, and may be appropriately selected and set according to the dosage form, etc. Specific examples of such container forms include a container for injections, a container for inhalants, a container for sprays, a bottle-shaped container, a tube-shaped container, a container for eye drops, a container for nasal drops, a container for ear drops, a bag container, etc. Furthermore, these containers may be further packaged in a box, a bag, etc.
[0027] The material (material) of the container is not particularly limited, and may be appropriately selected according to the shape of the container. Specific examples include glass, plastic, cellulose, pulp, rubber, metal, etc. From the viewpoint of processability, squeezability, and durability, it is preferable to use plastic. The resin of the plastic container is preferably a thermoplastic resin, and examples thereof include polyolefin-based resins such as low-density polyethylene (including linear low-density polyethylene), high-density polyethylene, medium-density polyethylene, polypropylene, and cyclic polyolefin; polyester-based resins such as polyethylene terephthalate, polybutylene terephthalate, polyethylene naphthalate, polybutylene naphthalate, and poly(1,4-cyclohexylene dimethylene terenaphthalate); polyphenylene ether-based resins; polycarbonate-based resins; polysulfone-based resins; polyamide-based resins; polyvinyl chloride resins; and styrene-based resins, and may be mixtures (polymer alloys) of these.
[0028] The disease to which the aqueous composition is applied is not particularly limited, and may be appropriately selected depending on the pharmacological action of brimonidine, etc. Specifically, for example, brimonidine can be used as a preventive or therapeutic agent for ocular hypertension and glaucoma based on its adrenaline α2 receptor activating action and intraocular pressure reducing action. More specifically, examples of glaucoma include primary open-angle glaucoma, normal tension glaucoma, aqueous humor hyperproduction glaucoma, acute angle-closure glaucoma, chronic angle-closure glaucoma, plateau iris syndrome, mixed glaucoma, steroid-induced glaucoma, crystalline capsular glaucoma, pigmentary glaucoma, amyloid glaucoma, neovascular glaucoma, and malignant glaucoma.
[0029] When the aqueous composition is used as an agent for the prevention and / or treatment of an eye disease (preferably a disease selected from ocular hypertension, glaucoma, and fundus disease; particularly preferably a disease selected from ocular hypertension and glaucoma), an appropriate amount (for example, about one drop in the case of eye drops) may be administered about 1 to 3 times a day, preferably about 1 to 2 times a day, depending on the expected level of medicinal effect.
[0030] In addition, the present specification discloses the following aspects of the invention, for example, but is not limited to these. [1A] The following components (A) and (B): (A) brimonidine or a salt thereof or a solvate thereof; (B) an amino compound; 1. An aqueous composition comprising: [2A] The aqueous composition described in [1A], wherein component (A) is brimonidine tartrate. [3A] The aqueous composition according to [1A] or [2A], wherein component (B) is one or more members selected from the group consisting of optionally substituted aliphatic amines, salts thereof, and solvates thereof. [4A] The aqueous composition according to any one of [1A] to [3A], wherein component (B) is one or more selected from the group consisting of aliphatic primary, secondary, and tertiary (preferably secondary) amines having 1 to 12 carbon atoms (preferably 2 to 10, particularly preferably 2 to 6 carbon atoms), which may have one or more (preferably 1 to 4) selected from the group consisting of a carboxyl group, a hydroxyl group, a sulfonic acid group, a guanidino group, a carbamoyl group, a mercapto group, an imidazolyl group, a methylthio group, and a phenyl group (preferably a carboxyl group, a hydroxyl group, a sulfonic acid group, a guanidino group, and an imidazolyl group) as a substituent, and salts thereof, and solvates thereof. [5A] The aqueous composition according to any one of [1A] to [4A], wherein component (B) is one or more members selected from the group consisting of aspartic acid, alanine, arginine, epsilon-aminocaproic acid, edetic acid, glycine, glutamine, glutamic acid, cystine, cysteine, histidine, phenylalanine, methionine, lysine, leucine, trometamol, monoethanolamine, taurine, ethylenediamine, chlorhexidine, edetic acid, salts thereof, and solvates thereof. [6A] The aqueous composition according to any one of [1A] to [5A], wherein component (B) is one or more members selected from the group consisting of chlorhexidine, chlorhexidine hydrochloride, chlorhexidine gluconate, chlorhexidine acetate, and solvates thereof. [7A] The aqueous composition according to any one of [1A] to [6A], which is an ophthalmic preparation. [8A] The aqueous composition described in [7A], which is an eye drop. [9A] The aqueous composition according to any one of [1A] to [8A], which is an agent for preventing and / or treating a disease selected from the group consisting of ocular hypertension and glaucoma. [10A] The aqueous composition according to any one of [1A] to [9A], which does not contain Ripasudil or a salt thereof, or a solvate thereof. [11A] A pharmaceutical product comprising the aqueous composition according to any one of [1A] to [10A] contained in a container.
[0031] [1B] The following component (A): (A) brimonidine or a salt thereof or a solvate thereof; The aqueous composition contains the following component (B): (B) an amino compound; A method for stabilizing brimonidine or a salt thereof, or a solvate thereof in an aqueous composition (preferably, a method for suppressing a decrease in the content), comprising: [2B] The method described in [1B], wherein component (A) is brimonidine tartrate. [3B] The method according to [1B] or [2B], wherein the component (B) is one or more members selected from the group consisting of an aliphatic amine which may have a substituent, a salt thereof, and a solvate thereof. [4B] The method according to any one of [1B] to [3B], wherein the component (B) is one or more selected from the group consisting of aliphatic primary to tertiary (preferably secondary) amines having 1 to 12 (preferably 2 to 10, particularly preferably 2 to 6) carbon atoms, which may have one or more (preferably 1 to 4) selected from the group consisting of a carboxyl group, a hydroxyl group, a sulfonic acid group, a guanidino group, a carbamoyl group, a mercapto group, an imidazolyl group, a methylthio group, and a phenyl group (preferably a carboxyl group, a hydroxyl group, a sulfonic acid group, a guanidino group, and an imidazolyl group) as a substituent, and salts thereof, and solvates thereof. [5B] The method according to any one of [1B] to [4B], wherein component (B) is one or more members selected from the group consisting of aspartic acid, alanine, arginine, epsilon-aminocaproic acid, edetic acid, glycine, glutamine, glutamic acid, cystine, cysteine, histidine, phenylalanine, methionine, lysine, leucine, trometamol, monoethanolamine, taurine, ethylenediamine, chlorhexidine, edetic acid, salts thereof, and solvates thereof. [6B] The method according to any one of [1B] to [5B], wherein component (B) is one or more members selected from the group consisting of chlorhexidine, chlorhexidine hydrochloride, chlorhexidine gluconate, chlorhexidine acetate, and solvates thereof. [7B] The method according to any one of [1B] to [6B], wherein the aqueous composition is an ophthalmic preparation. [8B] The method according to [7B], wherein the ophthalmic preparation is an eye drop. [9B] The method according to any one of [1B] to [8B], wherein the aqueous composition is an agent for preventing and / or treating a disease selected from the group consisting of ocular hypertension and glaucoma. [10B] The method according to any one of [1B] to [9B], wherein the aqueous composition does not contain Ripasudil or a salt thereof, or a solvate thereof. EXAMPLES
[0032] The present invention will now be described in further detail with reference to examples, but the present invention is not limited to these in any way.
[0033] [Test Example 1] Storage test (evaluation of stability of brimonidine) In order to evaluate the stability of brimonidine in the aqueous compositions, aqueous compositions of Example 1 and Comparative Example 1 containing the components and amounts shown in Table 1 per 100 mL were prepared by a conventional method. Each of the resulting aqueous compositions was stored at 80° C. for 1 day, and the remaining rate of brimonidine after storage was measured as follows. That is, for each aqueous composition before the start of storage and after storage for 1 day, the peak height was measured using an HPLC device, and the remaining rate (%) of brimonidine was calculated according to the following formula, which was used as an index of content reduction.
[0034] Residual rate of brimonidine (%) = peak height of brimonidine after storage / peak height of brimonidine before storage × 100
[0035] The results are shown in Table 1.
[0036] [Table 1]
[0037] As shown in Table 1, in the aqueous composition containing only brimonidine (Comparative Example 1), the residual rate of brimonidine was about 96.5% after storage at 80° C. for 1 day, resulting in a decrease in the content. On the other hand, in the aqueous composition containing chlorhexidine gluconate in addition to brimonidine (Example 1), there was substantially no decrease in the brimonidine content even after storage at 80° C. for 1 day.
[0038] From the results of Test Example 1 above, it became clear that the reduction in the brimonidine content can be suppressed by further adding an amino compound represented by one or more selected from the group consisting of chlorhexidine, its salts, and their solvates to an aqueous composition containing brimonidine or its salts, or their solvates.
[0039] [Manufacturing Examples 1-27] Aqueous compositions containing the components and amounts (amounts (g) per 100 mL of the aqueous composition) shown in Tables 2 to 4 can be produced by a conventional method.
[0040] [Table 2]
[0041] [Table 3]
[0042] [Table 4] [Industrial Applicability]
[0043] INDUSTRIAL APPLICABILITY According to the present invention, an aqueous composition having excellent stability can be provided, and can be suitably used in the pharmaceutical industry and the like.
Claims
[Claim 1] The invention described herein.
Citation Information
Patent Citations
Compositions containing alpha-2-adrenergic agonist components
JP2004504279A
Composition containing î±-2-adrenergic agonist component
JP2012246304A
